cis-Diprotected cyclams and cyclens: a new route to symmetrically or asymmetrically 1,4-disubstituted tetraazamacrocycles and to asymmetrically tetrasubstituted derivatives

Frédéric Bellouard,^{*a*} Françoise Chuburu,^{*a*} Nelly Kervarec,^{*b*} Loïc Toupet,^{*c*} Smaïl Triki,^{*a*} Yves Le Mest^{*a*} and Henri Handel *^{*a*}

^{*a*} UMR CNRS 6521 "Chimie, Electrochimie Moléculaires et Chimie Analytique" and ^{*b*} Service commun RMN-RPE, Université de Bretagne Occidentale, B. P. 809,

6 avenue Le Gorgeu, 29285 Brest cedex, France. E-mail: henri.handel@univ-brest.fr

^c UMR CNRS 6626, Université de Rennes 1, Campus de Beaulieu, F-35042 Rennes cedex, France

Received (in Cambridge, UK) 14th July 1999, Accepted 7th October 1999

The use of cyclam and cyclen oxamides as intermediates for the synthesis of N^1 , N^4 -disubstituted tetraazamacrocycles is reported. This pathway affords a general strategy for the preparation of symmetrically or asymmetrically disubstituted derivatives in good yields. Also these intermediates proved convenient synthons for the preparation of asymmetrically tetrasubstituted macrocycles, leading to a new class of potentially dinucleating ligands.

Introduction

Substituted tetraazamacrocycles, derivatives of cyclam and cyclen, constitute a wide family of ligands acting as receptors for a large range of metallic cations. Their versatility with regard to coordination of the metals is under the control of a number of factors including the functionalisation of the coordinating nitrogen. Indeed N-functionalisation has been revealed to be a remarkable tool for the synthesis of ligands possessing enhanced selectivity towards metal-ion coordination.¹ As a matter of fact, these substitution reactions afford the preparation of derivatives with tailored properties.

While a number of methods for the mono-N-alkylation of tetraazamacrocycles, such as either cyclen or cyclam, have been developed,²⁻⁵ very few strategies for their dialkylation have been reported. Selective dialkylation of cyclen has been described via derivatives temporarily diprotected by tosyl,6 methyl7 and phosphoryl⁸ groups, carbamates moieties,⁹ metal carbonyl¹⁰ or silicon intermediates.¹¹ In the case of cyclam, most dialkylated derivatives have been prepared according to multistep reaction schemes involving tosyl² or Boc¹² as protective groups. Unfortunately, the corresponding diprotected macrocycles are formed as a mixture also containing both the monoprotected and triprotected ones. In order to avoid such a drawback, new modes of protection have been recently described involving the use of dioxomacrocycles,¹³ cyclam formamidinium salt¹⁴ or methylene-bridged cyclam.¹⁵ However, most of these procedures only allow N¹,N⁷-functionalisation. To our knowledge only one N1,N4-dialkylation has been reported.16

In the present paper we report a general strategy for the selective N^1,N^4 -dialkylation of both cyclen and cyclam. Through the preparation of various derivatives, the extension of this method is established. Moreover it appears that this new synthetic approach opens the way to a new class of dimetallic chelating ligand.

Results and discussion

As a strategy for the selective dialkylation of cyclam and cyclen tetraazamacrocycles, the use of diprotective groups has been envisaged. Molecular mechanics calculations predicted that the oxamide group should properly fit the distance between the two adjacent nitrogens, *i.e.* N^1 , N^4 and the formation of the corresponding six-membered ring is preferred. Hereafter the numbering **a** and **b** designates, respectively, cyclam and cyclen derivatives.



Acylation of cyclam with diethyl oxalate leads to cyclamoxamide. A method previously reported by Krajewski¹⁷ gave a low overall yield (50%), unsatisfactory with regard to a synthetic demand. We attempted to enhance the yield of this reaction by acylation of cyclam 1a with oxalyl dichloride but this reaction led to a mixture containing unchanged 1a, cyclamoxamide 2a and the dibridged 3a. Optimisation of the yield and purity of the desired synthon was realised through reaction of cyclam 1a with equimolar amounts of diethyl oxalate by refluxing in ethanol under strictly anhydrous conditions; this afforded white needles of 2a in 82% yield after recrystallisation. We have extended this synthetic procedure to cyclen. Equimolar amounts of diethyl oxalate and cyclen 1b were allowed to react in absolute ethanol at room temperature, and the cyclenoxamide 2b was obtained in 96% yield. This new derivative was characterised by its five resonances in ¹³C NMR (42.9, 44.9, 47.6, 47.7, 160.2 ppm) and two signals in ¹⁵N NMR spectroscopy (-357.2, -270.4 ppm) corresponding, respectively, to two amine and two amide functions: these spectroscopic data established the proposed structure **2b** according to symmetry criteria.

The oxamide intermediate was revealed to be a powerful bisnucleophile. Under S_N^2 conditions, oxamides **2a** and **2b** were efficiently converted to the corresponding N¹,N⁴-dialkylated

J. Chem. Soc., Perkin Trans. 1, 1999, 3499–3505 3499

			cyclam		
		Yield (%)			Yield (%)
$\begin{array}{l} \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_2\mathbf{Ph} \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_2\mathbf{Py} \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_2\mathbf{COOBu'} \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{Pr} \end{array}$	4a 5a 6a 7a	87 86 96 85	$R' = R'' = CH_2Ph$ $R' = R'' = CH_2Py$ $R' = R'' = CH_2CO_2H^a$ R' = R'' = Pr	4a' 5a' 6a' 7a'	82 89 52 72
N ¹ ,N ⁴ -functionalised cyclenoxamide $0 \rightarrow N \rightarrow $		Yield (%)	N ¹ ,N ⁴ -functionalised cyclen $H \longrightarrow R'$ $H \longrightarrow R''$		Yield (%)
$\begin{aligned} \mathbf{R}' &= \mathbf{R}'' = \mathbf{CH}_2 \mathbf{Ph} \\ \mathbf{R}' &= \mathbf{R}'' = \mathbf{CH}_2 \mathbf{Py} \\ \mathbf{R}' &= \mathbf{R}'' = \mathbf{Pr} \end{aligned}$	4b 5b 6b	93 94 74	$\begin{aligned} \mathbf{R}' &= \mathbf{R}'' = \mathbf{C}\mathbf{H}_{2}\mathbf{P}\mathbf{h}\\ \mathbf{R}' &= \mathbf{R}'' = \mathbf{C}\mathbf{H}_{2}\mathbf{P}\mathbf{y}\\ \mathbf{R}' &= \mathbf{R}'' = \mathbf{P}\mathbf{r} \end{aligned}$	4b' 5b' 6b'	81 79 71
	$R' = R'' = CH_2Ph$ $R' = R'' = CH_2Ph$ $R' = R'' = CH_2Py$ $R' = R'' = CH_2COOBu'$ $R' = R'' = Pr$ N ¹ ,N ⁴ -functionalised cyclenoxamide $O = N = N = N = N$ $R' = R'' = CH_2Ph$ $R' = R'' = CH_2Ph$ $R' = R'' = CH_2Ph$ $R' = R'' = CH_2Py$ $R' = R'' = Pr$ thydrochloride salt.	$\begin{array}{c} \overbrace{N,N,N,R'}\\ \overbrace{O,N,N,R'}\\ \hline\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Ph} & \mathbf{4a}\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Py} & \mathbf{5a}\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{COOBu}' & \mathbf{6a}\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{Pr} & \mathbf{7a} \end{array}$ $\begin{array}{c} \mathbf{N}^{1},\mathbf{N}^{4}\text{-functionalised}\\ \text{cyclenoxamide} \\ \hline\\ \overbrace{O,N,N,R''}\\ \hline\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Ph} & \mathbf{4b}\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Py} & \mathbf{5b}\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{Pr} & \mathbf{6b} \end{array}$	$\begin{array}{c} \overbrace{N,N,N,R'}_{O,O,N,R'} & \underbrace{Yield}_{(?\%)} \\ \hline\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Ph} & \mathbf{4a} & 87 \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Py} & \mathbf{5a} & 86 \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{COOBu}' & \mathbf{6a} & 96 \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{Pr} & \mathbf{7a} & 85 \\ \hline\\ \mathbf{N}^{1}, \mathbf{N}^{4} - \mathbf{functionalised} \\ \mathbf{cyclenoxamide} & \\ \overbrace{O,N,N,R'',R''} & \underbrace{\mathbf{Yield}}_{(?\%)} \\ \hline\\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Ph} & \mathbf{4b} & 93 \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{CH}_{2}\mathbf{Py} & \mathbf{5b} & 94 \\ \mathbf{R}' = \mathbf{R}'' = \mathbf{Pr} & \mathbf{6b} & 74 \\ \hline \end{array}$	$\begin{array}{cccc} & & & & & & & & & & & & & & & & & $	$\begin{array}{cccc} & & & & & & & & & & & & & & & & & $



compounds 4a-7a, 4b-6b. These were readily hydrolysed under mild acidic or basic conditions into the corresponding N¹,N⁴dialkylated cyclams or cyclens 4a'-7a', 4b'-6b'. After subsequent purification, these derivatives were isolated in good yields (Scheme 1, Table 1). Moreover, resolution of X-ray structures for single crystals of the dibenzylated dioxocyclen 4b (Fig. 2) and of the dibenzylated cyclam $[4a^\prime,\,Ni^{II}]$ complex (Fig. 3) highlighted the N¹,N⁴ locations of the substituents. The metal ion is tetracoordinated in a square planar geometry; the central unit [NiN₄] is planar within 0.09 Å. The macrocycle is in a trans-III configuration, as expected for 1,8-dialkylated cyclams.¹⁸ Ni–N bonds are in the normal range;¹⁶ Ni–N(1), Ni-N(2) distances [respectively 1.979(7), 1.954(7) Å] are slightly longer than Ni-N(3) and Ni-N(4) ones [respectively 1.942(7), 1.943(7) Å] as a consequence of the alkylation on N(1) and N(2) atoms. Incidentally, these structures provide further evidence for the structures of the intermediate oxamide synthons.

Addition of the oxamides **2a** and **2b** to a Michael acceptor, *e.g.* acrylonitrile, opens up new interesting prospects since, according to experimental conditions, either symmetrical or asymmetrical dialkylation can be attained. Thus, in ethanol as solvent, excess of acrylonitrile led to the expected dinitriles N^1 , N^4 -cyclam or cyclen oxamide **8a**, **8b**. In pure acrylonitrile, mononitriles **9a** and **9b** were the major products, isolated in 78% and 67% yield (after chromatography) and only small amounts of dinitriles were detected. Under these conditions the kinetics for the linkage of the second group are sufficiently slowed to produce selectively the monoalkylated derivatives **9a** and **9b**.

The latter compounds proved useful for the grafting of another pendant arm to the macrocyclic skeleton and, for example, 9a and 9b after reaction with picolyl chloride and hydrolysis led to the asymmetrical macrocycles 9a'' and 9b'' (Scheme 2, Table 2).

Clearly, this synthetic scheme opens up the way to a new kind of tetraalkylated macrocycle. As an illustration, when dipicolylcyclam 5a' was allowed to react with tosylaziridine in acetonitrile solution ¹⁹ and the resulting tosylamide hydrolysed, the octamine **10'** is obtained in 78% yield (Scheme 3). This ligand appears to be a potentially binucleating agent towards metal ions.

Conclusions

These results emphasise the efficiency of the dioxo-bridge as a protective group for N^1, N^4 -functionalisation of cyclams and cyclens. The synthesis of cyclam and cyclen oxamides is easy and quantitative; removal of the protective group is carried out under mild basic or acidic conditions. This pathway allows the N-attachment of a wide variety of substituents, leading to disubstituted and even tetrasubstituted ligands.







Finally, protected disubstituted cyclens and cyclams can also be considered as precursors of reinforced cyclen and cyclam. This family of compounds has been shown to display (i) greater selectivity towards metal ions in terms of size matching²⁰ and (ii) some efficiency as proton sponges.²¹ Further work concerning all these aspects is currently in progress.

Experimental

¹H and ¹³C NMR spectra (400 and 100.62 MHz respectively) were acquired on a Bruker AC 400 spectrometer; *J* values are given in Hz. ¹⁵N NMR spectra were obtained as ¹H/¹⁵N correlations with HMBC sequence using a TBI probe. IR spectra were recorded on a Perkin-Elmer 1430. Mass spectra were obtained on a Navigator Finnigan in APCI positive mode (the

samples were diluted in MeOH or CH₃CN), and highresolution mass spectra were recorded using ZabSpecETOF FAB+ (*m*-NBA). TLC analyses were performed on silica or alumina plates (Merck 60 F_{254}). All the reactions were run under nitrogen using freshly distilled and dry solvents.

1,5,8,12-Tetraazabicyclo[10.2.2]hexadecane-13,14-dione 2a (cyclamoxamide)

Cyclam **1a** (5 mmol, 1.0 g) was dried by azeotropic distillation in 60 mL of toluene. After removal of solvent under reduced pressure, the residue was dissolved in dry ethanol (15 mL), and diethyl oxalate (5 mmol, 680 µL) was added. The reaction mixture was refluxed for 12 h. The solvent was rotary evaporated and the crude product was recrystallised in acetone–ethanol (20:1) to yield white crystals (82%), mp 166–168 °C; $\delta_{\rm H}$ (CDCl₃) 1.87 (2H, m, CH₂CH₂N), 1.97 (2H, m, CH₂CH₂N), 2.66 (4H, m, CH₂N), 2.75 (2H, m, CH₂N), 2.85 (2H, m, CH₂NCO), 2.98 (2H, m, CH₂N), 3.58 (2H, m, CH₂NCO), 3.94 (2H, m, CH₂NCO), 4.55 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 25.3 (CH₂-CH₂N), 44.1, 47.7 (CH₂NCO), 49.3, 49.8 (CH₂N), 158.1 (CO); ν (CH₂Cl₂)/cm⁻¹ 1675 (CO); *m*/z (APCI) 255.9 (M + H⁺).

1,4,7,10-Tetraazabicyclo[8.2.2]tetradecane-11,12-dione 2b (cyclenoxamide)

Cyclen (1,4,7,10-tetraazacyclododecane) **1b** (2 mmol, 416 mg) was dried by azeotropic distillation in 50 mL of toluene. After removal of solvent under reduced pressure, the residue was dissolved in dry ethanol (10 mL), and diethyl oxalate (2 mmol, 272

μL) was added. The reaction mixture was stirred for 48 h. Chromatography on silica gel (CHCl₃–isopropylamine, 5:1) yielded a white solid (96%), mp 96–98 °C; $R_{\rm f}$ 0.20; $\delta_{\rm H}$ 2.55 (2H, m, CH₂N), 2.63–2.70 (4H, m, CH₂N), 2.87–3.02 (4H, m, CH₂N) and CH₂NCO), 3.47–3.59 (4H, m, CH₂NCO), 3.68 (1H, d, *J* 13.6, NCH₂Py), 3.82 (1H, m, CH₂NCO), 4.12 (1H, m, CH₂NCO), 4.36 (1H, m, CH₂NCO), 4.47 (1H, m, CH₂NCO); $\delta_{\rm c}$ (CDCl₃) 42.9, 47.7 (CH₂NCO), 44.9, 47.6 (CH₂N), 160.2 (CO); *ν* (neat)/cm⁻¹ 1660 (CO); *m/z* HRMS (M + H⁺) (Calc. for C₁₀H₁₉N₄O₂: *M*, 227.1508; C, 53.0; H, 8.06; N, 24.7. Found: M⁺, 227.1502; C, 52.7; H, 8.0; N, 24.0%).

1,5,8,12-Tetraazatricyclo[10.2.2.2^{5,8}]octadecane-6,7,13,14tetraone 3a (cyclamdioxamide)

Cyclam **1a** (2 mmol, 400 mg) was dried by azeotropic distillation in 30 mL of toluene. After removal of solvent under reduced pressure, the residue was dissolved in dichloromethane (40 mL), and triethylamine (10 mmol, 1.4 mL) was added. The reaction mixture was cooled in an ice-bath, oxalyl dichloride (4 mmol, 350 µL) was added dropwise, and the mixture was stirred at room temperature overnight. The solvent and excess of triethylamine were rotary evaporated and the residue was recrystallised in acetonitrile to yield white crystals, suitable for X-ray analysis (36%), $\delta_{\rm H}$ (CDCl₃) 2.16 (4H, m, CH₂CH₂N), 2.87 (4H, dt, ³J 5.3, ²J 13.8, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 21.1 (CH₂-CH₂N), 43.9, 47.9 (CH₂NCO), 158.8 (CO); ν (CH₂Cl₂)/cm⁻¹ 1670 (CO); m/z (APCI) 309.2 (M + H⁺).

General procedure for dialkylation

Cyclamoxamide **2a** (1 mmol, 260 mg) or cyclenoxamide **2b** (1 mmol, 230 mg) in DMF (10 mL) was treated in the presence of Na₂CO₃ (2.2 mmol, 235 mg) with 2.2 equivalents of alkyl halide. The resulting reaction mixture was stirred for 3–6 h at 100 °C. After removal of solvent under reduced pressure, the residue was dissolved in dichloromethane and filtered. The crude product was chromatographed through alumina or silica gel.

5,8-Dibenzyl-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane-

13,14-dione 4a. This compound was purified by chromatography on alumina gel (CHCl₃) to yield a white solid (87%), $R_{\rm f}$ 0.45; $\delta_{\rm H}$ (CDCl₃) 1.65 (2H, m, CH₂CH₂N), 1.89 (2H, m, CH₂CH₂N), 2.41 (8H, m, CH₂N), 2.72 (2H, m, CH₂NCO), 3.46 (6H, m, CH₂NCO and NCH₂Ph), 4.05 (2H, m, CH₂NCO), 4.38 (2H, m, CH₂NCO), 7.15–7.28 (10H, m, Ph); $\delta_{\rm C}$ (CDCl₃) 23.7 (CH₂CH₂N), 44.4, 46.2 (CH₂NCO), 52.0, 52.2 (CH₂N), 57.5 (NCH₂Ph), 126.9, 128.0, 129.6, 137.5 (Ph), 158.4 (CO); ν (neat)/ cm⁻¹ 1670 (CO); *m/z* (APCI) 435.3 (M + H⁺).

5,8-Dipicolyl-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane-

13,14-dione 5a. This compound was purified by chromatography on silica gel (acetone–isopropylamine, 20:1) to yield a brown solid (86%), $R_{\rm f}$ 0.22; $\delta_{\rm H}$ 1.70 (2H, m, CH_2CH_2N), 1.88 (2H, m, CH_2CH_2N), 2.51–2.57 (8H, m, CH_2N), 2.70 (2H, m, CH_2NCO), 3.41 (2H, m, CH_2NCO), 3.58 (2H, d, J 13.9, NCH_2 -Py), 3.64 (2H, d, J 13.9, NCH_2Py), 4.02 (2H, m, CH_2NCO), 4.41 (2H, m, CH_2NCO), 7.12 (2H, m, $H_{\rm Ar}$), 7.28 (2H, d, J 7.8, $H_{\rm Ar}$), 7.59 (2H, dd, J 7.7, 1.7, $H_{\rm Ar}$), 8.49 (2H, d, J 4.1, $H_{\rm Ar}$); $\delta_{\rm C}$ (CDCl₃) 22.8 (CH_2CH_2N), 43.4, 45.3 (CH_2NCO), 53.0 (2C) (CH_2N), 58.4 (NCH_2Py), 121.1, 123.2, 135.3, 148.0, 157.5 ($C_{\rm Ar}$), 157.6 (CO); ν (neat)/cm⁻¹ 1660 (CO); m/z (APCI) 437.4 (M + H⁺); HRMS (M + H⁺) Calc. for $C_{24}H_{33}N_6O_2$: m/z, 437.2665. Found: m/z, 437.2669.

5,8-Bis(*tert*-butoxycarbonylmethyl)-1,5,8,12-tetraazabicyclo-[10.2.2]hexadecane-13,14-dione 6a. This compound was purified by chromatography on alumina gel (CHCl₃) to yield a colourless oil (96%), $R_f 0.38$; δ_H (CDCl₃) 1.38 [18H, s, (CH₃)₃C], 1.64 (2H, m, CH₂CH₂N), 1.80 (2H, m, CH₂CH₂N), 2.54–2.75 (10H, m, CH₂N), 3.13 (2H, d, *J* 16.8, NCH₂CO₂Bu'), 3.25 (2H, d, *J* 16.8, NCH₂CO₂Bu'), 3.34 (2H, m, CH₂NCO), 3.90 (2H, m, CH₂NCO), 4.37 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 22.5 (*C*H₂-CH₂N), 27.6 [(*C*H₃)₃C], 43.8, 46.1 (*C*H₂NCO), 51.1, 52.1, 53.5 (*C*H₂N), 81.1 [(CH₃)₃C], 157.9 (NCO), 169.8 (*C*O₂Bu'); $\delta_{\rm N}$ (CDCl₃) – 347.3 (NCH₂CO₂Bu'), –263.2 (CH₂NCO); ν (neat)/ cm⁻¹ 1670 (CO_{oxamide}), 1725 (CO_{ester}).

5,8-Dipropyl-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane-

13,14-dione 7a. This compound was purified by chromatography on alumina gel (CHCl₃) to yield a white solid (85%), $R_{\rm f}$ 0.58; $\delta_{\rm H}$ (CDCl₃) 0.65 (6H, t, *J* 7.3, CH₃CH₂), 1.19 (4H, m, CH₃CH₂CH₂N), 1.47–1.70 (4H, m, CH₂CH₂N), 2.06–2.27 (12H, m, CH₂N), 2.59 (2H, m, CH₂NCO), 3.22 (2H, m, CH₂NCO), 3.80 (2H, m, CH₂NCO), 4.17 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 11.6 (CH₃CH₂), 17.0 (CH₃CH₂CH₂N), 23.4 (CH₂-CH₂N), 43.8, 45.9 (CH₂NCO), 51.8, 52.0, 54.6 (CH₂N), 158.0 (CO); $\delta_{\rm N}$ (CDCl₃) –340.5 (NCH₂CH₂CH₃), –264.2 (CH₂-NCO); ν (neat)/cm⁻¹ 1660 (CO); *m*/*z* (APCI) 339.4 (M + H⁺).

5,8-Bis(2-cyanoethyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane-13,14-dione 8a. This compound was prepared from cyclamoxamide (1 mmol, 260 mg) in a mixture of ethanol (10 mL) and acrylonitrile (5 mL). The reaction mixture was refluxed for 48 h, and the solvent and the excess of reagent were evaporated to yield a colourless oil (98%), $\delta_{\rm H}$ 1.81 (4H, m, CH₂CH₂N), 2.43–2.63 (14H, m, CH₂N and CH₂CN), 2.71–2.80 (4H, m, CH₂NCO), 3.42 (2H, m, CH₂NCO), 3.91 (2H, m, CH₂NCO), 4.40 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 13.6 (CH₂CN), 23.0 (CH₂CH₂N), 43.5, 45.6 (CH₂NCO), 48.6, 51.9, 52.3 (CH₂N), 119.0 (CH₂CN), 157.8 (CO); ν (neat)/cm⁻¹ 1660 (CO), 2240 (CN); *m*/*z* (APCI) 361.4 (M + H⁺, 90%), 721.5 (dimer + H⁺, 100).

5-(2-Cyanoethyl)-1,5,8,12-tetraazabicyclo[10.2.2]hexadecane-13,14-dione 9a. This compound was prepared from cyclamoxamide (1 mmol, 260 mg) in acrylonitrile (10 mL). The reaction mixture was refluxed for 48 h and the excess of reagent was evaporated. Chromatography on silica gel (CHCl₃–isopropylamine, 50:1) yielded a colourless oil (78%), *R*_f 0.46; *δ*_H 1.56–1.77 (4H, m, CH₂CH₂N), 2.30–2.91 (16H, m, CH₂N, CH₂CN and CH₂NCO), 3.61 (2H, m, CH₂NCO), 4.47 (2H, m, CH₂NCO); *δ*_C (CDCl₃) 12.6 (CH₂CN), 22.1, 25.8 (CH₂CH₂N), 41.7, 43.6, 45.3, 46.5 (2C), 47.6, 48.5, 52.0, 53.2 (CH₂N), 118.9 (CH₂CN), 157.4, 157.7 (CO); *ν* (neat)/cm⁻¹ 1660 (CO), 2240 (CN); *m*/*z* (APCI) 308.3 (M + H⁺).

5-(2-Cyanoethyl)-8-(2-picolyl)-1,5,8,12-tetraazabicyclo-

[10.2.2]hexadecane-13,14-dione 9a'. 5-(2-Cyanoethyl)-1,5,8,12tetraazabicyclo[10.2.2]hexadecane-13,14-dione (0.5 mmol, 155 mg) was dissolved in DMF (10 mL). Na₂CO₃ (2 mmol, 212 mg) and 2-picoline hydrochloride (0.5 mmol, 135 mg) were added. The reaction mixture was stirred at 100 °C for 4 h. After removal of solvent under reduced pressure, the residue was dissolved in dichloromethane and filtrated. Chromatography on silica gel (CHCl₃-isopropylamine, 10:1) yielded a yellow oil (81%), $R_{\rm f}$ 0.41; $\delta_{\rm H}$ 1.77–2.06 (6H, m, CH_2CH_2N and CH_2CN), 2.32-2.81 (16H, m, CH₂N and CH₂NCO), 3.34 (1H, m, CH₂NCO), 3.46 (1H, m, CH₂NCO), 3.57 (1H, d, J 13.6, NCH₂Py), 3.68 (1H, d, J 13.6, NCH₂Py), 3.82 (1H, m, CH₂-NCO), 4.12 (1H, m, CH₂NCO), 4.36 (1H, m, CH₂NCO), 4.47 (1H, m, CH₂NCO), 7.17 (1H, m, H_{Ar}), 7.32 (1H, d, *J* 7.7, H_{Ar}), 7.66 (1H, m, H_{Ar}), 8.63 (1H, m, H_{Ar}); $\delta_{\rm C}$ (CDCl₃) 12.9 (CH₂CN), 22.5, 23.2 (CH₂CH₂N), 43.1, 43.6, 45.0, 47.6, 47.8, 48.5, 51.2, 51.7, 52.5 (CH₂N), 118.9 (CH₂CN), 121.5, 123.3, 135.6, 148.2, 157.2 (C_{Ar}), 157.6, 157.8 (CO); v (neat)/cm⁻¹ 1660 (CO), 2240 (CN); m/z (APCI) 399.2 (M + H⁺).

1,4-Dipicolyl-8,11-bis(*p*-tolylsulfonamidoethyl)-1,4,8,11-tetraazacyclotetradecane 10. This compound was prepared from 5a' (1 mmol, 382 mg) by reaction with tosylaziridine (2 mmol, 392 mg) in acetonitrile (15 mL). The reaction mixture was refluxed for 48 h. Chromatography on silica gel (CHCl₃–isopropylamine, 10:1) yielded a brown oil (91%), R_f 0.61; δ_H (CDCl₃) 1.59 (4H, m, CH₂CH₂N), 2.31 (4H, m, CH₂N), 2.40 (10H, m, CH₂N and CH₃C₆H₄SO₂), 2.52 (10H, m, CH₂N), 3.01 (4H, m, CH₂NHTs), 3.51 (4H, s, NCH₂Py), 7.10 (2H, m, H_{Py}), 7.28 (4H, m, C₆H₄), 7.40 (2H, d, *J* 7.6, H_{Py}), 7.49 (2H, m, H_{Py}), 7.77 (4H, m, C₆H₄), 8.46 (2H, d, *J* 4.1, H_{Py}); δ_C (CDCl₃) 20.9 (CH₃C₆H₄SO₂), 23.9 (CH₂CH₂N), 40.1 (CH₂NHTs), 49.6 (2C), 50.7 (2C), 51.6 (CH₂N), 59.8 (NCH₂Py), 121.4, 122.3, 135.6, 147.9 (C₆H₄), 126.3, 129.1, 137.1, 142.2, 159.7 (C_{Py}); *m/z* (FAB) 777.3945 (M + H⁺, 100%).

1,4-Bis(2-aminoethyl)-8,11-dipicolyl-1,4,8,11-tetraazacyclotetradecane 10'. Compound 10 (1 mmol, 778 mg) was detosylated in conc. sulfuric acid (5 mL). The reaction mixture was stirred at 90 °C for 72 h. Ethanol (30 mL) and diethyl ether (30 mL) were slowly added to the cooled black mixture. The protonated octamine sulfate was precipitated, filtered off and washed with diethyl ether $(2 \times 10 \text{ mL})$. The sulfate salt was neutralised with cooled 10 M NaOH solution. The product was extracted with dichloromethane. The octamine was obtained as a colourless oil (86%), $\delta_{\rm H}$ (CDCl₃) 1.70 (4H, m, CH₂CH₂N), 2.50-2.60 (20H, m, CH₂N), 2.95 (4H, m, CH₂NH₂), 3.57 (4H, s, NCH₂Py), 5.25 (4H, s, NH), 7.13 (2H, m, H_{Py}), 7.33 (2H, d, J 7.8, H_{Py}), 7.56 (2H, m, H_{Py}), 8.51 (2H, d, J 4.5, H_{Py}); δ_C (CDCl₃) 24.5 (CH₂CH₂N), 37.8 (CH₂NH₂), 50.8 (2C), 51.6, 52.0, 52.1 (CH₂N), 60.4 (NCH₂Py), 122.0, 123.5, 136.3, 148.9, 159.3 (C_{Py}); $\delta_{\rm N}$ (CDCl₃) -73.3 (N_{Py}), -343.2, -350.2 (CH₂N), -359.4 (CH₂NH₂); *m*/*z* (APCI) 469.5 (M + H⁺).

4,7-Dibenzyl-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-

11,12-dione 4b. This compound was purified by chromatography on silica gel (CHCl₃-isopropylamine, 15:1) to yield a white solid (93%), mp 150–152 °C. Crystals, suitable for X-ray analysis, were obtained in toluene. $R_{\rm f}$ 0.41; $\delta_{\rm H}$ (CDCl₃) 2.29 (2H, m, CH₂N), 2.40–2.66 (6H, m, CH₂N), 2.90 (2H, m, CH₂NCO), 3.34–3.51 (6H, m, CH₂NCO and NCH₂Ph), 4.11–4.23 (4H, m, CH₂NCO), 7.12 (4H, m, H_{Ar}), 7.30 (6H, m, H_{Ar}); $\delta_{\rm C}$ (CDCl₃) 46.4, 48.7, 51.8, 54.7 (CH₂N), 57.9 (NCH₂Ph), 126.7, 127.7, 129.3, 137.7 (C_{Ar}) 159.3 (CO); ν (neat)/cm⁻¹ 1670 (CO); *m*/*z* HRMS (M + H⁺) Calc. for C₂₄H₃₁N₄O₂: *m*/*z*, 407.2447. Found: *m*/*z*, 407.2466.

4,7-Dipicolyl-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-

11,12-dione 5b. This compound was purified by chromatography on silica gel (acetone–isopropylamine, 20:1) to yield a brown solid (94%), mp 138–140 °C; $R_{\rm f}$ 0.23; $\delta_{\rm H}$ 2.34–2.60 (8H, m, CH₂N), 2.82 (2H, m, CH₂NCO), 3.35 (2H, m, CH₂NCO), 3.47 (4H, m, NCH₂Py), 3.95 (2H, m, CH₂NCO), 4.14 (2H, m, CH₂NCO), 7.04 (4H, m, H_{Ar}), 7.50 (2H, t, *J* 7.6, 1.7, H_{Ar}), 8.40 (2H, m, H_{Ar}); $\delta_{\rm C}$ (CDCl₃) 45.5, 47.9 (CH₂NCO), 51.6, 54.4 (CH₂N), 58.0 (NCH₂Py), 121.6, 123.7, 135.8, 148.3, 157.9 (C_{Ar}), 159.5 (CO); ν (neat)/cm⁻¹ 1670 (CO); *m*/*z* HRMS (M + H⁺) Calc. for C₂₂H₂₉N₆O₂: *m*/*z*, 409.2352. Found: *m*/*z*, 409.2359.

4,7-Dipropyl-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-

11,12-dione 6b. This compound was purified by chromatography on silica gel (CHCl₃-isopropylamine, 7:1) to yield a yellow solid (74%), $R_f 0.56; \delta_H 0.87$ (6H, t, $J7.3, CH_3$), 1.42 (4H, m, CH_2CH_3), 2.17 (2H, m, CH_2N), 2.31–2.40 (6H, m, CH_2N and CH_2NCO), 2.49 (2H, m, CH_2N), 2.72–2.84 (4H, m, CH_2N), 3.47 (2H, m, CH_2NCO), 4.17 (4H, m, CH_2NCO); δ_C (CDCl₃) 11.8 (CH₃), 19.5 (CH_2CH_3), 47.0, 49.6, 52.2, 55.9, 56.0 (CH_2N), 159.4 (CO); ν (neat)/cm⁻¹ 1660 (CO); m/z (FAB) 311.2448 (M + H⁺, 100%).

4,7-Bis(2-cyanoethyl)-1,4,7,10-tetraazabicyclo[8.2.2]tetra-

decane-11,12-dione 8b. This compound was prepared from

cyclenoxamide (1 mmol, 230 mg) in a mixture of ethanol (10 mL) and acrylonitrile (5 mL). The reaction mixture was refluxed for 48 h and the solvent and the excess of reagent were evaporated to yield a white solid, which was chromatographed on silica gel (CHCl₃–isopropylamine, 10:1) (87%), mp 180–182 °C; $R_{\rm f}$ 0.35; $\delta_{\rm H}$ 2.45 (10H, m, CH₂N and CH₂CN), 2.76 (8H, m, CH₂N and CH₂NCO), 3.51 (2H, m, CH₂NCO), 3.83 (2H, m, CH₂NCO), 4.24 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 13.4 (CH₂CN), 45.0, 47.4, 47.6, 50.7, 53.3 (CH₂N), 119.0 (CH₂CN), 159.4 (CO); ν (neat)/cm⁻¹ 1660 (CO), 2240 (CN); *m*/*z* (APCI) 333.3 (M + H⁺).

4-(2-Cyanoethyl)-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-11,12-dione 9b. This compound was prepared from cyclenoxamide (1 mmol, 230 mg) in acrylonitrile (10 mL). The reaction mixture was refluxed for 48 h and the excess of reagent was evaporated. Chromatography on silica gel (CHCl₃– isopropylamine, 7:1) yielded a yellow solid (67%), mp 182– 184 °C; $R_{\rm f}$ 0.29; $\delta_{\rm H}$ 2.32–2.94 (14H, m, CH₂N, CH₂CN and CH₂NCO), 3.19 (1H, m, CH₂NCO), 3.44 (1H, m, CH₂NCO), 3.63 (2H, m, CH₂NCO), 4.23 (2H, m, CH₂NCO); $\delta_{\rm C}$ (CDCl₃) 14.3 (CH₂CN), 42.4, 44.6, 45.7, 46.6, 48.3, 48.4, 48.7, 49.2, 53.8 (CH₂N), 118.7 (CH₂CN), 159.3, 160.7 (CO); ν (neat)/cm⁻¹ 1660 (CO), 2240 (CN); *m*/*z* (APCI) 280.2 (M + H⁺).

4-(2-Cyanoethyl)-7-(2-picolyl)-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-11,12-dione 9b'. 4-(2-Cyanoethyl)-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-11,12-dione 9b (0.5 mmol) was dissolved in DMF (10 mL). Na₂CO₃ (2 mmol, 212 mg) and 2-picoline hydrochloride (0.5 mmol, 135 mg) were added. The reaction mixture was stirred at 100 °C for 4 h. After removal of solvent under reduced pressure, the residue was dissolved in dichloromethane and filtered. Chromatography on silica gel (CHCl₃-isopropylamine, 7:1) yielded a brown solid (83%), mp 148–150 °C; $R_{\rm f}$ 0.47; $\delta_{\rm H}$ 2.33 (2H, t, J 6.6, CH₂CN), 2.43– 2.93 (8H, m, CH₂N), 3.46-3.53 (4H, m, CH₂NCO), 3.68 (1H, d, J 13.6, NCH₂Py), 3.77 (1H, d, J 13.6, NCH₂Py), 3.84 (1H, m, CH₂NCO), 4.05 (1H, m, CH₂NCO), 4.26 (2H, m, CH₂NCO), 7.12 (1H, m, H_{Ar}), 7.30 (1H, d, H_{Ar}), 7.60 (1H, m, H_{Ar}), 8.45 (1H, m, H_{Ar}); δ_c (CDCl₃) 13.0 (CH₂CN), 44.5 (2C), 46.7, 47.0 (2C), 50.3, 50.7, 53.1, 53.2, 57.1 (CH₂N), 118.6 (CH₂CN), 121.3, 123.3, 135.5, 147.8, 157.0 (C_{Ar}), 159.0, 159.4 (CO); v (neat)/cm⁻¹ 1670 (CO), 2240 (CN); m/z (APCI) 371.3 $(M + H^{+}).$

General procedure for hydrolysis

Disubstituted cyclamoxamide or cyclenoxamide was dissolved in water (5 mL) and NaOH (10 M; 5 mL) was added. The reaction mixture was stirred at 90 °C overnight. The product was extracted with dichloromethane. The solvent was rotary evaporated. The disubstituted tetramine was transformed into the hydrochloride salt for elemental analysis. Dropwise addition of HCl–ethanol solution induced precipitation of the hydrochloride salt, which was washed twice with ethanol and dried *in vacuo*.

1,4-Dibenzyl-1,4,8,11-tetraazacyclotetradecane 4a'. This compound was prepared from **4a** following the general procedure (colourless oil, 82%), $\delta_{\rm H}$ (CDCl₃) 1.78 (4H, m, CH₂CH₂N), 2.39 (8H, m, CH₂N), 2.78 (2H, m, CH₂N), 2.87 (4H, s, CH₂N), 3.43 (4H, s, NCH₂Ph), 7.21–7.30 (10H, m, Ph); $\delta_{\rm C}$ (CDCl₃) 25.4 (CH₂CH₂N), 46.5, 46.9, 51.5, 51.6 (CH₂N), 57.6 (NCH₂Ph), 126.7, 127.9, 129.1, 138.4 (Ph), 158.4 (CO); *m/z* (APCI) 381.4 (M + H⁺).

Complex [Ni(4a')](ClO₄)₂. A methanolic solution of Ni(ClO₄)₂·6H₂O (0.1 mmol, 36 mg) was added to a methanolic solution of the ligand 4a' (0.1 mmol, 37 mg). The mixture was refluxed for 1 h. After cooling, the precipitate was recrystallised

in CH₃CN (79% yield), λ_{max} (CH₃CN) 478 nm. Orange rhombohedral crystals, suitable for X-ray analysis, were obtained by slow evaporation of an acetonitrile solution.

1,4-Dipicolyl-1,4,8,11-tetraazacyclotetradecane 5a'. This compound was prepared from **5**a following the general procedure (yellow oil, 89%), $\delta_{\rm H}$ (CDCl₃) 1.75 (4H, m, CH₂CH₂N), 2.46 (8H, m, CH₂N), 2.72 (2H, m, CH₂N), 2.83 (4H, s, CH₂N), 3.58 (4H, s, NCH₂Py), 7.10 (2H, m, H_{Ar}), 7.41 (2H, d, *J* 7.8, H_{Ar}), 7.58 (2H, m, H_{Ar}), 8.49 (2H, d, *J* 4.1, H_{Ar}); $\delta_{\rm C}$ (CDCl₃) 25.4 (CH₂CH₂N), 45.9, 46.6, 51.1, 51.9 (CH₂N), 59.0 (NCH₂-Py), 121.4, 122.9, 135.6, 148.4, 158.8 (C_{Ar}); *m*/*z* HRMS (M + H⁺) Calc. for C₂₂H₃₅N₆: *m*/*z*, 383.2923. Found: *m*/*z*, 383.2922 (Calc. for C₂₂H₄₀Cl₆N₆: C, 43.9; H, 6.7; N, 14.0%. Found: C, 44.0; H, 6.5; N, 14.0).

1,4-Bis(carboxymethyl)-1,4,8,11-tetraazacyclotetradecane

tetrahydrochloride 6a'. This compound was prepared from 6a hydrolysed in 6 M HCl (10 mL). The acidic solution was stirred at 90 °C for 14 h. The solvent was rotary evaporated and the crude product was recrystallised in water–ethanol to yield a white solid (52%),† $\delta_{\rm H}$ (D₂O) 2.02 (4H, m, CH₂CH₂N), 3.04 (8H, m, CH₂N), 3.35 (4H, m, CH₂N), 3.48 (4H, s, CH₂N), 3.70 (4H, s, NCH₂CO₂H); $\delta_{\rm C}$ (D₂O) 22.5 (CH₂CH₂N), 42.2, 45.6, 52.2, 54.3 (CH₂N), 57.7 (NCH₂CO₂H), 173.2 (CO₂H); ν (KBr)/cm⁻¹ 1730 (CO₂H); *m/z* (APCI) 317.3 (M + H⁺).

1,4-Dipropyl-1,4,8,11-tetraazacyclotetradecane 7a'. This compound was prepared from 7a following the general procedure (colourless oil, 72%), $\delta_{\rm H}$ (CDCl₃) 0.84 (6H, t, *J* 7.4, CH₃CH₂), 1.45 (4H, m, CH₃CH₂CH₂N), 1.70 (4H, m, CH₂-CH₂N), 2.31 (2H, m, CH₂N), 2.46 (10H, m, CH₂N), 2.64 (4H, m, CH₂N), 2.72 (4H, s, CH₂N), 2.84 (2H, s, NH); $\delta_{\rm C}$ (CDCl₃) 11.8 (CH₃CH₂), 18.6 (CH₃CH₂CH₂N), 25.4 (CH₂CH₂N), 46.5, 46.6, 51.4, 51.9, 54.8 (CH₂N); *m*/*z* (APCI) 285.4 (M + H⁺); HRMS (M + H⁺) Calc. for C₁₆H₃₇N₄: *m*/*z*, 285.3018. Found: *m*/*z*, 285.3025.

1,4-Bis(2-carboxyethyl)-1,4,8,11-tetraazacyclotetradecane

tetrahydrochloride 8a'. This compound was prepared from 8a hydrolysed in 6 M HCl (10 mL). The acidic solution was stirred at 90 °C for 48 h. The solvent was rotary evaporated and the crude product was recrystallised in water–ethanol to yield a white solid (59%), mp 160–162 °C; $\delta_{\rm H}$ (D₂O) 2.18 (4H, m, CH₂CH₂N), 2.94 (4H, s, NCH₂CH₂CO₂H), 3.28–3.79 (20H, m, CH₂N); $\delta_{\rm C}$ (D₂O) 20.5 (CH₂CH₂N), 31.9 (NCH₂CH₂CO₂H), 39.6, 43.2, 47.1, 50.9, 54.2 (CH₂N), 176.3 (CO₂H); ν (KBr)/cm⁻¹ 1720 (CO) (Calc. for C₁₆H₃₆Cl₄N₄O₄. 2H₂O: C, 36.5; H, 7.7; N, 10.6%. Found: C, 36.3; H, 7.9; N, 10.5).

1-(2-Carboxyethyl)-4-picolyl-1,4,8,11-tetraazacyclotetra-

decane 9a". This compound was prepared from 9a' hydrolysed in 6 M HCl (10 mL). The acidic solution was stirred at 90 °C for 48 h. The solvent was rotary evaporated and the crude product was recrystallised in water–ethanol to yield a white solid (51%), $\delta_{\rm H}$ (D₂O) 1.94 (2H, m, CH₂CH₂N), 2.25 (2H, m, CH₂CH₂N), 2.68 (2H, t, J 6.6, CH₂CO₂H), 2.89 (2H, t, J 6.6, NCH₂CH₂-CO₂H), 3.07–3.63 (16H, m, CH₂N), 4.11 (2H, s, NCH₂Py), 7.97 (1H, t, J 6.6, H_{Py}), 8.03 (1H, d, J 7.9, H_{Py}), 8.54 (1H, m, H_{Py}), 8.74 (1H, d, J 5.1, H_{Py}); $\delta_{\rm C}$ (D₂O) 21.1, 23.8 (CH₂CH₂N), 31.5 (CH₂CO₂H), 40.5, 40.7, 43.9, 45.0, 48.3, 51.3, 52.4, 53.3, 53.7 (CH₂N), 58.4 (NCH₂Py), 129.3, 130.4, 144.2, 150.3, 154.9 (C_{Py}), 176.3 (CO₂H); v (KBr)/cm⁻¹ 1720 (CO₂H); m/z (APCI) 364.8 (M + H⁺).

1,4-Dibenzyl-1,4,7,10-tetraazacyclododecane 4b'. This compound was prepared from 4b following the general procedure (colourless oil, 81%), $\delta_{\rm H}$ (CDCl₃) 2.58 (8H, m, CH₂N), 2.76 (4H, m, CH₂N), 2.84 (4H, s, CH₂N), 3.48 (4H, s, NCH₂Ph), 7.23–7.38 (10H, m, Ph); $\delta_{\rm C}$ (CDCl₃) 44.6, 46.2, 50.2, 51.5 (CH₂N), 57.8 (NCH₂Ph), 126.7, 127.9, 129.0, 138.2 (Ph); *m/z* HRMS (M + H⁺) Calc. for C₂₂H₃₃N₄: *m/z*, 353.2705. Found: *m/z*, 353.2726 (Calc. for C₂₂H₃₆Cl₄N₄·H₂O: C, 51.2; H, 7.4; N, 10.8%. Found: C, 51.2; H, 7.6; N, 10.7).

1,4-Dipicolyl-1,4,7,10-tetraazacyclododecane 5b'. This compound was prepared from **5b** following the general procedure (brown oil, 79%), $\delta_{\rm H}$ (CDCl₃) 2.67 (8H, m, CH₂N), 2.85 (4H, m, CH₂N), 2.93 (4H, s, CH₂N), 3.64 (4H, s, NCH₂Py), 7.10 (2H, m, H_{Ar}), 7.32 (2H, d, *J* 7.7, H_{Ar}), 7.48 (2H, dt, *J* 7.6, 1.8, H_{Ar}), 8.52 (2H, d, *J* 4.2, H_{Ar}); $\delta_{\rm C}$ (CDCl₃) 44.5, 45.8, 50.6, 51.4 (CH₂N), 58.6 (NCH₂Py), 121.4, 122.8, 135.8, 148.3, 158.1 (C_{Ar}); *m*/*z* (APCI) 355.3 (M + H⁺).

1,4-Dipropyl-1,4,7,10-tetraazacyclododecane 6b'. This compound was prepared from **6b** following the general procedure (colourless oil, 71%), $\delta_{\rm H}$ (CDCl₃) 0.88 (6H, t, *J* 7.3, CH₃CH₂), 1.45 (4H, m, CH₃CH₂CH₂N), 2.40–2.56 (12H, m, CH₂N), 2.71 (4H, m, CH₂N), 2.80 (4H, m, CH₂N); $\delta_{\rm C}$ (CDCl₃) 11.7 (CH₃CH₂), 18.9 (CH₃CH₂CH₂N), 45.2, 46.5, 50.9, 51.5, 55.3 (CH₂N); *m/z* (FAB) 257.2505 (M + H⁺; 100%).

1,4-Bis(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane tetrahydrochloride 8b'. This compound was prepared from **8b** hydrolysed in 6 M HCl (10 mL). The acidic solution was stirred at 90 °C for 48 h. The solvent was rotary evaporated and the crude product was recrystallised in water–ethanol to yield a white solid (58%),† $\delta_{\rm H}$ (D₂O) 2.75 (4H, m, CH₂CO₂H), 2.95 (4H, m, NCH₂CH₂CO₂H), 3.06–3.24 (16H, m, CH₂N); $\delta_{\rm C}$ (D₂O) 31.0 (NCH₂CH₂CO₂H), 44.1, 45.2, 45.9, 50.9, 51.3 (CH₂N), 177.3 (CO₂H); ν (KBr)/cm⁻¹ 1720 (CO); *m*/*z* HRMS (M + H⁺) Calc. for C₁₄H₂₉N₄O₄: *m*/*z*, 317.2189. Found: *m*/*z*, 317.2192.

1-(2-Carboxyethyl)-4-picolyl-1,4,7,10-tetraazacyclododecane tetrahydrochloride 9b". This compound was prepared from **9b**' hydrolysed in 6 M HCl (10 mL). The acidic solution was stirred at 90 °C for 24 h. The solvent was rotary evaporated and the crude product was recrystallised in water–ethanol to yield a white solid (49%),† $\delta_{\rm H}$ (D₂O) 2.89–3.51 (20H, m, CH₂N and CH₂CO₂H), 4.17 (2H, s, NCH₂Py), 7.97 (1H, t, *J* 6.2, H_{Py}), 8.04 (1H, d, *J* 8.0, H_{Py}), 8.55 (1H, t, *J* 8.0, H_{Py}), 8.72 (1H, d, *J* 5.9, H_{Py}); $\delta_{\rm C}$ (D₂O) 30.0 (CH₂CO₂H), 43.3, 44.9, 45.0, 46.9, 50.1, 50.6, 52.5, 53.0, 54.5, 56.4 (CH₂N), 129.6, 131.5, 145.0, 150.4, 152.4 (C_{Py}), 177.7 (CO₂H); ν (KBr)/cm⁻¹ 1720 (CO₂H); *m*/*z* (FAB) 336.2400 (M + H⁺, 100%).

Single-crystal X-ray diffraction ‡

Compound 3a. $C_{14}H_{20}N_4O_4$, M = 308.34, monoclinic, $P2_1/c$, a = 7.190(8), b = 8.080(4), c = 12.279(12) Å, $\beta = 102.40(9)^\circ$, V = 697(1) Å³, Z = 2, λ (Mo-K α) = 0.710 73 Å, $\mu = 1.10$ cm⁻¹, F(000) = 328, $D_{calc} = 1.470$ g cm⁻³, T = 293 K. Refinement of 111 variables gave R = 0.077, $R_w = 0.181$ and $S_w = 0.973$ (residual $\Delta \rho \le 0.409$ e Å⁻³) by using 600 reflections with $I > 2\sigma(I)$. The structure is presented in Fig. 1.

Compound 4b. $C_{24}H_{30}N_4O_2 \cdot \frac{1}{2}H_2O$, M = 415.52, monoclinic, $P2_1/a$, a = 13.465(3), b = 12.608(4), c = 14.504(3) Å, $\beta = 116.85(3)^\circ$, V = 2197(1) Å³, Z = 4, $\lambda(Mo-K\alpha) = 0.710$ 73 Å, $\mu = 0.84$ cm⁻¹, F(000) = 912, $D_{calc} = 1.257$ g cm⁻³, T = 293 K, 5000 reflections measured. Refinement of 272 variables gave R = 0.049, $R_w = 0.130$ and $S_w = 1.035$ (residual $\Delta \rho \le 0.255$ e Å⁻³) by using 2946 reflections with $I > 2.0\sigma(I)$. The structure is presented in Fig. 2.

[†] Hydrochloride salts decomposed when heated.

[‡] CCDC reference number 207/369. See http://www.rsc.org/suppdata/ p1/1999/3499 for crystallographic files in .cif format.



Fig. 1 ORTEP diagram of the molecular structure of 1,5,8,12-tetraazatricyclo[10.2.2.2^{5,8}]octadecane-6,7,13,14-tetraone **3a**, with crystallographic numbering scheme.



Fig. 2 ORTEP diagram of the molecular structure of 1,4-dibenzyl-1,4,7,10-tetraazabicyclo[8.2.2]tetradecane-11,12-dione **4b**, with crystal-lographic numbering scheme.



Fig. 3 ORTEP diagram of the molecular structure of the complex $[Ni(4a')](ClO_4)_2$, with crystallographic numbering scheme.

Complex [Ni(4a')](ClO₄)₂. C₂₄H₃₆Cl₂N₄NiO₈, M = 638.19, monoclinic, $P_{2_1/c}$, a = 9.785(1), b = 27.604(3), c = 10.306(1) Å, $\beta = 91.55(2)^{\circ}$, V = 2783(1) Å³, Z = 4, λ (Mo-K α) = 0.710 73 Å, $\mu = 9.45$ cm⁻¹, F(000) = 1336, $D_{calc} = 1.523$ g cm⁻³, T = 294 K, 5312 reflections measured. Refinement of 352 variables gave R = 0.054, $R_w = 0.061$ and G.O.F = 1.083 (residual $\Delta \rho \le 0.471$ $e \ \text{Å}^{-3}$) by using 1719 reflections with $I > 1.5\sigma(I)$. The structure is presented in Fig. 3.

Acknowledgements

This work was supported by the Centre National de la Recherche Scientifique (UMR CNRS 6521) and the Ministère de l'Enseignement Supérieur, de la Recherche et de la Technologie (doctoral grant for F. B.). Dr D. Picart (UBO), Dr P. Guénot (Centre Régional de Mesures Physiques de l'Ouest) and Dr M. Liu Gonzalez are gratefully acknowledged for recording, respectively, APCI, HRMS spectra and crystallographic data.

References

- 1 (a) A. Bianchi, M. Micheloni and P. Paoletti, Coord. Chem. Rev., 1991, **110**, 17; (b) K. Wainwright, Coord. Chem. Rev., 1997, **166**, 35.
- 2 J. M. Helps, D. Parker, J. P. Morphy and J. Chapman, *Tetrahedron*, 1989, **45**, 219.
- 3 E. Kimura, S. Aoki, T. Koike and M. Shiro, J. Am. Chem. Soc., 1997, 119, 3068.
- 4 (a) D. H. Busch, Chem. Rev., 1993, 93, 847; (b) L. F. Lindoy, The Chemistry of Macrocycle Ligand Complexes, Cambridge University Press, Cambridge, 1989.
- 5 (a) A. Filali, J. J. Yaouanc and H. Handel, *Angew. Chem.*, *Int. Ed. Engl.*, 1991, **30**, 560; (b) N. Oget, F. Chuburu, J. J. Yaouanc and H. Handel, *Tetrahedron*, 1996, **52**, 2995.
- 6 A. Dumont, V. Jacques, P. Qixiu and J. F. Desreux, *Tetrahedron Lett.*, 1994, 35, 3707.
- 7 M. Ciampolini, M. Micheloni, N. Nardi, P. Paoletti, P. Dapporto and F. Zanobini, J. Chem. Soc., Dalton Trans., 1984, 1357.
- 8 I. Gardinier, H. Bernard, F. Chuburu, A. Roignant, J. J. Yaouanc and H. Handel, *Chem. Commun.*, 1996, 2157.
- 9 Z. Kovacs and A. D. Sherry, J. Chem. Soc., Chem. Commun., 1995, 185.
- 10 V. Patinec, J. J. Yaouanc, J. C. Clement, H. Handel and H. des Abbayes, *Inorg. Chim. Acta*, 1994, **220**, 347.
- 11 A. Roignant, I. Gardinier, H. Bernard, J. J. Yaouanc and H. Handel, J. Chem. Soc., Chem. Commun., 1995, 1233.
- 12 B. Boitrel, B. Andrioletti, M. Lachkar and R. Guilard, *Tetrahedron Lett.*, 1995, 36, 4995.
- 13 M. A. Santos, M. Gaspar, M. L. S. Simoes Gonçalves and M. T. Amorim, *Inorg. Chim. Acta*, 1998, 278, 51.
- 14 P. J. Davies, M. R. Taylor and K. P. Wainwright, *Chem. Commun.*, 1998, 827.
- 15 G. Royal, V. Dahaoui Gindrey, S. Dahaoui, A. Tabard, R. Guilard, P. Pullumbi and C. Lecomte, *Eur. J. Org. Chem.*, 1998, 1971.
- 16 M. R. Oberholzer, M. Neuburger, M. Zehnder and T. A. Kaden, *Helv. Chim. Acta*, 1995, **78**, 505.
- 17 J. W. Krajewski, P. Gluzinski, R. A. Kolinski, A. Kemme and A. Mishnev, *Pol. J. Chem.*, 1994, **68**, 703.
- 18 J. Chapman, G. Ferguson, J. F. Gallagher, M. C. Jennings and D. Parker, J. Chem. Soc., Dalton Trans., 1992, 345.
- 19 I. Murase, M. Mikuriya, M. Sonoda, Y. Fukuda and S. Kida, J. Chem. Soc., Dalton Trans., 1986, 953.
- 20 T. J. Hubin, J. M. Cormick, S. R. Collinson, N. W. Alcock and D. M. Busch, *Chem. Commun.*, 1998, 1675.
- 21 S. T. Howard and I. A. Fallis, J. Org. Chem., 1998, 63, 7117.

Paper 9/05701C